Please login to the form below
spondyloarthritis
This page shows the latest spondyloarthritis news and features for those working in and with pharma, biotech and healthcare.
Cosentyx, Entresto drive topline growth for Novartis in Q4
The IL-17 inhibitor has continued to outpace expectations, and has been stacking up indications, with the most recent filing for approval in non-radiographic axial spondyloarthritis.
Latest news
-
Novartis’ Cosentyx misses the mark in Humira head-to-head
These results are a blow for Novartis, especially after the resounding positive results it unveiled at the beginning of the month for Cosentyx in non-radiographic axial spondyloarthritis (nr-axSpA).
-
Novartis grows in Q3 thanks to stellar performance of key drugs
This could be helped with a new approval in non-radiographic axial spondyloarthritis (nr-axSpA) – Novartis reported positive phase 3 data for Consentyx in this indication earlier this month, as it
-
Novartis’ Cosentyx scores again in phase 3, strengthens approval claim
Scopes approval in non-radiographic axial spondyloarthritis. Novartis has unveiled more positive phase 3 data for Cosentyx, this time in patients with non-radiographic axial spondyloarthritis (nr-axSpA). .
-
Novartis eyes potential new indication for Cosentyx
The new data comes from the Swiss pharma’s PREVENT trial, in patients with non-radiographic axial spondyloarthritis (nr-axSpA). ... earlier in axial spondyloarthritis,” said John Tsai (pictured below), head of global drug development and chief
-
UCB supports social network for SpA patients
MySpondylitisTeam is launched by MyHealthTeams. UCB has partnered with MyHealthTeams to launch a new social network called MySpondylitisTeam for patients with the chronic and inflammatory arthritis spondyloarthritis (SpA). ... Eric Peacock, co-founder
Novartis’ Cosentyx misses the mark in Humira head-to-head
Novartis grows in Q3 thanks to stellar performance of key drugs
Novartis’ Cosentyx scores again in phase 3, strengthens approval claim
UCB supports social network for SpA patients
More from news
Approximately 4 fully matching, plus 13 partially matching documents found.
Latest from PMHub
-
Lucid Group make the cut at the PMEAs 2017
Category: Supporting Patients and Professionals. DUET: Harnessing the Power of Collaboration from Concept to Completion – Improving Patient Care in Spondyloarthritis, by AbbVie, with support from Lucid Group.
-
Infographic: Spondyloarthritis
Overview of spondyloarthritis patient profiles and treatment pathways. Spondyloarthritis is the name for a family of arthritis causing inflammatory rheumatic diseases; including axial spondyloarthritis, psoriatic arthritis and akylosing spondylitis,
-
Research Partnership
Infographic: Spondyloarthritis. ... Overview of spondyloarthritis patient profiles and treatment pathways.
More from PMHub
Approximately 1 fully matching, plus 2 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Senior Account Management Trainer, Medical Communications, Londo...
-
Highly competitive salary
-
CEO Pricing & Market Access, UK
-
Six figure salary
- Senior Account Director, Medical & Brand Communications, Lon...
-
Highly competitive salary
- Home Working Medical Copy Writer & Senior Medical Copy Write...
-
Highly Competitive Salary, Bonus &Benefits
- Account Director, Medical & Brand Communications, London/ SE...
-
Highly competitive salary
- Editorial Director - UK, , EUROPE, REMOTE.
-
Highly Competitive Salary, Bonus &Benefits
- Freelance Scientific Director, Medical Communications, London/ S...
-
Highly competitive salary
- Medical Writers (All levels) Editorial / Scientific Leads & ...
-
Highly Competitive Remuneration packages
- Embattled Biogen talks up Aduhelm
- First oral antiviral drug for COVID-19 reviewed by Health Canada
- David Hunt launches independent agency The Considered
- EU “still interested” in Valneva COVID vaccine despite UK snub
- One dose of AZ’s COVID-19 vaccine ‘highly effective’ against severe disease from variants
- FDA’s director and deputy director of its Office of Vaccines Research & Review resign
- New data from Moderna supports COVID boosters
- $47.5m research centre to seek genetic insights into disease
- Havas Life Medicom and ARK lead at 2021 PM Society Digital Awards
- Nicky Hutchens appointed as deputy managing director at Four Health
- Health For All
- Digitalizing Muskuloskeletal Care to Improve Patient Outcomes and Reduce Cost
- Oxford PharmaGenesis wins Communiqué Medical Affairs Agency of the Year award at Communiqué 2021
- bluebird bio gears up for split
- FDA’s director and deputy director of its Office of Vaccines Research & Review resign
- Oxford PharmaGenesis wins Communiqué Medical Affairs Agency of the Year award at Communiqué 2021
- If the shoe fits
- Initiative Health welcomes Life Sciences by Stickyeyes
PMHub
Oxford University Press
Oxford University Press publishes over 100 prestigious, highly cited, and authoritative medical journals, many in collaboration with some of the...
Latest intelligence
- Health literacy in the time of COVID-19
- In a time when much of the media’s focus is on the ongoing COVID-19 pandemic and the differences in vaccination rates between various regions, countries, and socioeconomic groups, improving health...
- Rare thoughts & outcomes - navigating pathways to better outcomes in rare
- ...
- How to pick the perfect training program for your healthcare professionals
- You know your team needs training. But not all training providers and programs are created equal. Last week, we shared the benefits of working with specialist learning and development (L&D)...
